CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER (CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER).
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% provides exogenous amino acids and carbohydrates for parenteral nutrition. Amino acids are used for protein synthesis and nitrogen balance; dextrose provides caloric energy. The specific amino acid profile supports anabolism and tissue repair.
| Metabolism | Amino acids undergo transamination, deamination, and incorporation into proteins in various tissues. Dextrose is metabolized via glycolysis and the Krebs cycle primarily in the liver and peripheral tissues. No specific enzyme induction or inhibition is associated. |
| Excretion | Renal: amino acids and dextrose metabolites; hepatic: CO2 production. Urea nitrogen excretion accounts for ~80% of nitrogen elimination. |
| Half-life | Not applicable as a fixed combination; dextrose has a plasma half-life of ~2 hours, amino acids are metabolized continuously. |
| Protein binding | Amino acids: minimal (<10%); dextrose: not bound. |
| Volume of Distribution | Amino acids: 0.5 L/kg (total body water); dextrose: 0.2 L/kg. |
| Bioavailability | IV: 100%. |
| Onset of Action | IV: Immediate onset of nutritional support upon infusion start. |
| Duration of Action | Duration of action limited to infusion period; effects on nitrogen balance persist for 24 hours post-infusion. |
Intravenous infusion; typical adult dose is 500-1000 mL (providing 2.75% amino acids and 5% dextrose) infused at a rate not exceeding 100 mL/hour initially, adjusted based on metabolic and fluid requirements; continuous or intermittent infusion.
| Dosage form | INJECTABLE |
| Renal impairment | In acute kidney injury (GFR <15 mL/min/1.73 m²), reduce nitrogen content; use lower infusion rate and monitor BUN/serum electrolytes; for GFR 15-30, reduce dose by 50% and monitor; GFR >30, standard dosing with monitoring of renal function. |
| Liver impairment | Child-Pugh Class A/B: use with caution, monitor ammonia and serum amino acids; Class C: avoid use due to risk of hepatic encephalopathy; if used, reduce dose by 50% and monitor neurologic status. |
| Pediatric use | Weight-based: 2.5-3.5 g amino acids/kg/day (equivalent to 90-127 mL/kg/day); infuse at 0.5-1.0 mL/kg/hour initially, titrate to glucose tolerance; monitor serum electrolytes and glucose. |
| Geriatric use | Lower initial infusion rate (e.g., 50 mL/hour) with gradual titration; monitor renal function (creatinine clearance) and fluid balance; avoid excessive fluid load in heart failure; consider reduced calorie requirements. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER (CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER).
| Breastfeeding | Breastfeeding safety: Caution advised. CLINIMIX components (amino acids, dextrose, electrolytes) are normally present in breast milk at low levels. No specific M/P ratio data available. Use only if clearly needed and monitor infant for potential adverse effects (e.g., hyperglycemia, electrolyte disturbances). |
| Teratogenic Risk | No specific teratogenic risk profile; CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% is a parenteral nutrition solution containing amino acids, electrolytes, and dextrose. There are no adequate and well-controlled studies in pregnant women. Based on animal reproduction studies, there is no evidence of fetal harm at clinically relevant doses. However, use during pregnancy should be reserved for cases where clear clinical benefit justifies potential risks. First trimester: No known teratogenic effects. Second and third trimesters: No specific risks reported; but maternal metabolic stability is essential. |
■ FDA Black Box Warning
None (no FDA boxed warning for this product).
| Serious Effects |
["Hypersensitivity to any component (amino acids, dextrose, sulfites).","Severe hyperglycemia or metabolic acidosis.","Hepatic coma or severe hepatic insufficiency.","Severe renal impairment without appropriate electrolyte adjustments."]
| Precautions | ["Monitor fluid and electrolyte balance, blood glucose, and liver function.","Risk of hyperglycemia, especially in stressed or diabetic patients.","Hepatic steatosis with prolonged use or excessive caloric load.","Do not administer simultaneously with blood products through same infusion line.","Contain sulfites; may cause allergic reactions in sulfite-sensitive patients (rare)."] |
| Food/Dietary | As this is a parenteral nutrition product, there are no direct food interactions. However, oral intake should be carefully reintroduced as tolerated once the underlying condition improves. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes, blood glucose, renal function, fluid balance, and nutritional status. Fetal monitoring: Assess fetal growth and well-being via ultrasound and non-stress tests as clinically indicated. During infusion, watch for signs of fluid overload or metabolic imbalances. |
| Fertility Effects | No known adverse effects on fertility in animal studies. In clinical practice, appropriate nutritional support may improve fertility in malnourished women. No specific human data on reproductive impact. |
| Clinical Pearls | This is a parenteral nutrition formulation providing 2.75% amino acids and 5% dextrose, free of sulfites. It should only be used when oral/enteral nutrition is impossible or inadequate. Monitor for hyperglycemia, fluid overload, and electrolyte imbalances. Do not administer peripherally unless diluted to appropriate osmolarity; central line recommended. Check for incompatibilities with other IV additives. |
| Patient Advice | This medication is given intravenously to provide nutrition when you cannot eat. · Tell your nurse if you experience pain, redness, or swelling at the IV site. · Report symptoms of high blood sugar such as excessive thirst, frequent urination, or headache. · Do not stop or change the rate of infusion yourself. |